Thursday, March 11, 2010

Torrent Pharma Buy, Target Price-Rs538

Torrent Pharma (TRP@IN; Buy, Target Price-Rs538)

n    Torrent Pharma has signed a deal with Astra Zeneca for 15 products in 9 emerging markets

n    Revenue from these products will start contributing from FY11E onwards

n    Some of the products have already been developed by Torrent and few more will be developed

n    Torrent Pharma has not disclosed any financial details but we believe that there will be some upfront payment

n    We expect a revenue upside of US$15-20mn in next 2-3 years from this deal

n    Company has indicated that it is a routine deal

n    As of now we are not changing our earning estimates for FY11E and FY12E; waiting for more clarity

n    We view this development as positive one and re-iterate our Buy rating on Torrent Pharma.

--
Safe Harbor:
The information contained and provided on this Website provides Investment advice for the education of investors. The posts are an information service only. Recommendations, opinions or suggestions are given with the understanding that readers acting on this information assume all risks involved. We do not assume any responsibility or liability resulting from the use of such information, judgment and opinions for Trading or Investment purposes.
 
You received this message because you are subscribed to the Google Groups "Investors Please Listen !" group.
To post to this group, send email to investorspleaselisten@googlegroups.com
To unsubscribe from this group, send email to
investorspleaselisten+unsubscribe@googlegroups.com For more options, visit this group at http://groups.google.com/group/investorspleaselisten?hl=en

No comments:

Blog Archive

Life Insurance | Health Insurance | Auto Insurance


Investors Please Listen !

 
More than 100 kinds of Insurance products from more than
20 companies under one roof.



Call: 9818269396 
investorspleaselisten@in.com
www.investorspleaselisten.blogspot.com

 

 

Safe Harbor:

The information contained and provided on this Website provides Investment advice for the education of investors. The posts are an information service only. Recommendations, opinions or suggestions are given with the understanding that readers acting on this information assume all risks involved. We do not assume any responsibility or liability resulting from the use of such information, judgment and opinions for Trading or Investment purposes.
Powered by Olark
Advertising Learn to Invest